Production of humanised antibodies to TNFα
US7186820B2 · kind B2 · utility
5Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2001 |
| Grant date | Mar 6, 2007 |
| Priority date | — |
| Expiry date | May 10, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.